Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma
| العنوان: | Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma |
|---|---|
| المؤلفون: | Olivier Hermine, Hervé Dombret, Joel Poupon, Bertrand Arnulf, Francois Lefrère, Phillippe Rousselot, Gandhi Damaj, Richard Delarue, Jean Paul Fermand, Jean Claude Brouet, Laurent Degos, Bruno Varet, Hugues de Thé, Ali Bazarbachi |
| المساهمون: | Pathologie et virologie moléculaire (PVM (UMR_7151)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| المصدر: | Hematological Oncology Hematological Oncology, Wiley, 2004, 5, pp.130-134 |
| بيانات النشر: | Springer Science and Business Media LLC, 2004. |
| سنة النشر: | 2004 |
| مصطلحات موضوعية: | Adult, medicine.medical_specialty, Anti-HIV Agents, medicine.medical_treatment, Alpha interferon, Antineoplastic Agents, Gastroenterology, Arsenicals, Adult T-cell leukemia/lymphoma, 03 medical and health sciences, Zidovudine, chemistry.chemical_compound, 0302 clinical medicine, Arsenic Trioxide, Recurrence, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Leukemia-Lymphoma, Adult T-Cell, Arsenic trioxide, 030304 developmental biology, Human T-lymphotropic virus 1, 0303 health sciences, Chemotherapy, business.industry, Interferon-alpha, Oxides, Hematology, Middle Aged, Prognosis, medicine.disease, 3. Good health, Lymphoma, Leukemia, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Injections, Intravenous, Female, business, Progressive disease, medicine.drug |
| الوصف: | Human T-cell lymphotropic virus type 1 associated adult T-cell leukemia/lymphoma carries a very poor prognosis due to its intrinsic resistance to chemotherapy. Although zidovudine (AZT) and alpha-interferon (IFN) yield some responses and improve ATL prognosis, alternative therapies are needed. Arsenic trioxide (As) dramatically synergizes with IFN to induce growth arrest and apoptosis of ATL leukemia cells in vitro. These results prompted us to initiate a phase II trial of As/IFN combination in seven patients with relapsed/refractory ATL (four acute and three lymphoma). Four patients exhibited a clear initial response (one complete remission and three partial remissions). Yet, the treatment was discontinued after a median of 22 days because of toxicity (three patients) or subsequent progression (four patients). Six patients eventually died from progressive disease (five patients) or infection (one patient), but the remaining patient is still alive and disease free at 32 months. Pharmacokinetic studies showed that maximum arsenic blood levels (median 0.46 microM) were slowly achieved (8-15 days). In conclusion, arsenic/IFN treatment is feasible and exhibits an anti-leukemia effect in very poor prognosis ATL patients despite a significant toxicity. Future studies should assess the best timing for arsenic therapy: frontline with IFN/AZT or as maintenance after induction. |
| تدمد: | 1476-5632 1466-4860 0278-0232 1099-1069 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c450da2e0220f59872181913b029eedcTest https://doi.org/10.1038/sj.thj.6200374Test |
| رقم الانضمام: | edsair.doi.dedup.....c450da2e0220f59872181913b029eedc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765632 14664860 02780232 10991069 |
|---|